Gilead Sciences remains a bullish pick, with raised guidance and strong Q3/25 results driving optimism for continued growth. Gilead Sciences' key growth drivers include robust sales from Livdelzi and ...

Sprint Biosciences has sold its oncology programme to Gilead Sciences, which functions by blocking TREX1. Image credit: Sundry Photography via Shutterstock.com. Gilead Sciences has secured the rights ...

The company, which has invested heavily in oncology in recent years, is looking for new options as Trodelvy lags expectations and competition increases. At the same time, Gilead is facing increased ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead Sciences for $14 million upfront, plus the chance to net up to $400 million in biobucks. Last year, ...

– Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. – The funding focuses on reducing barriers to fresh food in vulnerable communities ...

Editor's note: The Fierce team will be out of office next Friday for the Thanksgiving holiday. The next edition of Chutes & Ladders will publish Dec. 5. Welcome to this week's Chutes & Ladders, our ...

Gilead Sciences, Inc. continues to outperform, driven by its dominant HIV division and strong Q3 results that surpassed analyst expectations. GILD's HIV portfolio, led by Biktarvy and new launch ...

Deborah Telman, Gilead Sciences Inc.'s top lawyer for the past three years, is relinquishing her duties as general counsel and head of corporate affairs effective Dec. 5. No reason was given Wednesday ...

Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining about 4%. With steady annual revenue and net income growth, there is renewed ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Deborah Telman is exiting months after the company paid $202 million to settle allegations that it provided illegal kickbacks to health care providers to juice sales of its HIV drugs. Deborah Telman ...